Eleven Biotherapeutics Inc. (EBIO) Stock Price Down 5.1%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares fell 5.1% during trading on Wednesday . The company traded as low as $4.40 and last traded at $4.49, with a volume of 593,570 shares changing hands. The stock had previously closed at $4.73.
The company’s 50-day moving average price is $3.93 and its 200-day moving average price is $1.78. The firm’s market cap is $75.12 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
In other Eleven Biotherapeutics news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $2.74, for a total transaction of $2,855,080.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.